Jamieson is pleased to announce that it has advised Dr. Miroslav Reljanović (Founder and Executive Chairman) and the management team of Ergomed plc on the rollover arrangements and terms of the management incentive plan in connection with the take private of the business by funds advised by Permira for £703m.
Ergomed is a differentiated Pharmacovigilance (“PV”) and Contract Research Organisation (“CRO”) platform with a strong track record in the complex oncology and rare diseases spaces and a reputation for high-quality, bespoke, customer centric delivery across its services. Ergomed operates in growing markets which benefit from increasing complexity, regulatory requirements and outsourcing rates. Dr. Miroslav Reljanović, founder and Executive Chairman, and the management team have made strong progress in recent years, strengthening both CRO and PV capabilities organically and through acquisitions.
Ian Jamieson, Stephen Maxwell, Alexander Wilson and Helen Briscoe advised Dr. Miroslav Reljanović and the management team.
